Athersys, Inc – Biotech Pinning Hopes on Stem Cell Therapy Product Buys Time with deferred Payment of $26.8mn Owed Key Supplier
Athersys, Inc (NASDAQ: ATHX) announced (with 8-K here) it has reached an agreement with a supplier critical to "the scale-up and manufacturing of clinical and commercial grade MultiStem® using Athersys’ bioreactor production processes." Further to the agreement, Athersys will pay the supplier $11.8mn in monthly cash payments of $250,000 each, beginning October 2023 and will…